GleamWall
中文EN

ANAB ANAPTYSBIO, INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1370053 · Fiscal year ends 06/30

Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY107.7%
TTM net income YoY81.0%
TTM EPS YoY78.1%
Revenue 3-yr CAGR179.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin35.9%
Net margin-11.5%
FCF margin1.9%
EBITDA margin36.0%

Returns

ROE-114.6%
ROA-7.1%
ROIC (approx.)—
Asset turnover0.62x

Leverage & solvency

Liabilities / assets96.1%
Debt / equity0.00x
Current ratio7.58x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.17x
Accruals ratio-8.3%
Payout ratio—
Capex / revenue0.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2027Q12026-09-302026Q4*2026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$30.27M$27.49M$25.56M$108.25M$76.32M$22.26M$27.77M$43.11M
R&D expense——$33.99M$25.56M$31.41M$37.82M$41.18M$42.59M
SG&A expense$11.64M-$2.81M$26.20M$15.79M$1.08M$10.61M$14.13M$10.19M
Operating income$19.91M$66.96M-$34.64M$66.90M$77.27M-$26.17M-$27.54M-$9.67M
Pretax income$3.27M$47.75M-$52.84M$49.70M$56.62M-$38.59M-$39.28M-$21.79M
Income tax-$608,000-$181.49M$40,000$81,000$269,000$39,000$44,000-$6,000
Net income$3.88M$183.88M-$52.88M$49.61M$15.11M-$38.63M-$39.33M-$21.78M
EBITDA$19.91M$66.84M-$34.51M$67.03M$77.28M-$26.03M-$27.39M-$9.53M
EPS (basic)0.13—-1.84—0.54-1.34-1.28—
EPS (diluted)0.11—-1.84—0.52-1.34-1.28—
Weighted avg. shares (diluted)35.07M—28.69M—29.02M28.81M30.64M—
Balance sheet
Cash & equivalents$135.39M$133.83M$248.47M$138.20M$9.83M$0$98.64M$23.08M
Short-term investments$17.60M$30.32M$37.99M$73.44M$139.12M$221.41M$241.30M$262.29M
Receivables$30.49M$25.63M$25.75M$33.85M$75.69M$21.42M$17.88M$40.77M
Current assets$188.37M$198.43M$316.11M$350.25M$330.65M$291.91M$363.11M$431.88M
PP&E, net$97,000$102,000$1.28M$111,000$1.50M$1.63M$1.74M$131,000
Total assets$307.04M$316.98M$329.68M$364.39M$353.10M$335.25M$422.05M$483.83M
Current liabilities$22.42M$35.35M$41.70M$38.62M$38.10M$35.53M$44.04M$45.43M
Total liabilities$286.22M$306.40M$316.94M$327.19M$382.51M$379.98M$388.03M$412.97M
Shareholders' equity$20.82M$10.59M$12.75M$37.21M-$29.42M-$44.73M$34.02M$70.87M
Shares outstanding29.94M29.73M29.03M28.02M27.58M27.97M30.39M30.47M
Cash flow statement
Operating cash flow-$9.54M-$26.64M-$25.92M$98.00M-$27.36M-$40.24M-$10.70M-$66.67M
Capital expenditure——$17,000$1,000$12,000$39,000$35,000$263,000
Free cash flow——-$25.94M$98.00M-$27.37M-$40.28M-$10.73M-$66.94M
Investing cash flow$12.59M$7.56M$34.98M$73.50M$47.58M$36.40M$14.85M-$29.40M
Financing cash flow-$1.48M-$95.56M$1.21M-$43.13M-$10.39M-$50.50M-$28.59M$27.57M
Depreciation & amortization$5,000-$121,000$130,000$131,000$4,000$142,000$146,000$145,000
Stock-based compensation$3.21M-$5.90M$14.22M$8.51M$207,000$9.24M$9.17M$8.18M
Share buybacks$0$0$0$3.38M$9.72M$51.10M$4.42M$456,000

Free plan shows the latest 8 periods; Pro shows all 43 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.